OncoMed Pharmaceuticals, Inc. (OMED) financial statements (2021 and earlier)

Company profile

Business Address 800 CHESAPEAKE DRIVE
REDWOOD CITY, CA 94063
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:57103185157232275
Cash and cash equivalents1013373828209
Short-term investments4890148119204107
Other undisclosed cash, cash equivalents, and short-term investments(0)0000(41)
Receivables    0 
Assets held-for-sale, not part of disposal group1   
Other undisclosed current assets52574944
Total current assets:64105190231241319
Noncurrent Assets
Property, plant and equipment134555
Other noncurrent assets1212210
Total noncurrent assets:1567715
TOTAL ASSETS:65110195238248334
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6713182326
Accounts payable235746
Accrued liabilities449111510
Employee-related liabilities    4 
Taxes payable     11
Deferred rent credit0
Restructuring reserve 0   
Deferred revenue and credits8221221936
Contract with customer, liability4
Other undisclosed current liabilities342212(4)0
Total current liabilities:139356533962
Noncurrent Liabilities
Liabilities, other than long-term debt466163182133154
Deferred revenue and credits65162181133152
Accounts payable and accrued liabilities 0000 
Accrued income taxes2
Deferred rent credit4
Other liabilities0     
Other undisclosed noncurrent liabilities    00
Total noncurrent liabilities:466163182133154
Total liabilities:17159219234171216
Stockholders' equity
Stockholders' equity attributable to parent48(49)(23)476118
Common stock000000
Additional paid in capital410403390313301293
Accumulated other comprehensive income (loss)(0)000(0)0
Accumulated deficit(362)(452)(413)(310)(224)(174)
Total stockholders' equity:48(49)(23)476118
TOTAL LIABILITIES AND EQUITY:65110195238248334

Income statement (P&L) ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net3825264038
Gross profit:443825264038
Operating expenses(54)(79)(129)(111)(90)(62)
Operating loss:(10)(41)(103)(86)(51)(24)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes    0(0)
Loss from continuing operations before equity method investments, income taxes:(10)(41)(103)(86)(51)(24)
Other undisclosed income from continuing operations before income taxes2100  
Loss from continuing operations before income taxes:(8)(40)(103)(85)(51)(24)
Income tax expense (benefit)01(0)(0)1(2)
Net loss available to common stockholders, diluted:(8)(39)(103)(85)(50)(26)

Comprehensive Income ($ in millions)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(8)(39)(103)(85)(50)(26)
Comprehensive loss:(8)(39)(103)(85)(50)(26)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)000(0)(0)
Comprehensive loss, net of tax, attributable to parent:(8)(39)(103)(85)(50)(26)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: